​

Larimar Therapeutics Stock (NASDAQ:LRMR)

ForecastOwnershipFinancialsChartTranscripts
Larimar Therapeutics by TradingView

Previous Close

$4.40

52W Range

$1.73 - $6.42

50D Avg

$4.68

200D Avg

$3.99

Market Cap

$371.41M

Avg Vol (3M)

$4.25M

Beta

1.02

Div Yield

-

LRMR Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

65

IPO Date

Jun 19, 2014

Website

LRMR Performance

LRMR Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-172.50M$-90.89M$-41.76M
Net Income$-165.67M$-80.60M$-36.95M
EBITDA$-172.50M$-90.57M$-41.45M
Basic EPS-$-1.32$-0.84
Diluted EPS-$-1.32$-0.84

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 23Sep 29, 25 | 1:45 PM

Peer Comparison

TickerCompany
ACIUAC Immune S.A.
LXEOLexeo Therapeutics, Inc. Common Stock
ALTAltimmune, Inc.
ANNXAnnexon, Inc.
ANROAlto Neuroscience, Inc.
KYTXKyverna Therapeutics, Inc.
ENGNenGene Holdings Inc.
DBVTDBV Technologies S.A.
AMRNAmarin Corporation plc
KRROKorro Bio, Inc.